OncoTherapy Science, Inc. (FRA:30O)
Germany
· Delayed Price · Currency is EUR 0.0915
-0.0050 (-5.18%)
At close: Dec 5, 2025
OncoTherapy Science Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 956 | 750 | 610 | 1,134 | 1,153 | 332 | Upgrade
|
| Revenue Growth (YoY) | 99.58% | 22.95% | -46.21% | -1.65% | 247.29% | 5.06% | Upgrade
|
| Cost of Revenue | 1,390 | 1,253 | 1,465 | 1,810 | 2,770 | 1,689 | Upgrade
|
| Gross Profit | -434 | -503 | -855 | -676 | -1,617 | -1,357 | Upgrade
|
| Selling, General & Admin | 303 | 289 | 261 | 287 | 294 | 281 | Upgrade
|
| Other Operating Expenses | 5 | 5 | 4 | 144 | 142 | - | Upgrade
|
| Operating Expenses | 308 | 294 | 265 | 431 | 436 | 281 | Upgrade
|
| Operating Income | -742 | -797 | -1,120 | -1,107 | -2,053 | -1,638 | Upgrade
|
| Interest Expense | -1 | -1 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1 | -5 | -8 | -14 | -3 | Upgrade
|
| Other Non Operating Income (Expenses) | -22 | -18 | -12 | -18 | -5 | 1 | Upgrade
|
| EBT Excluding Unusual Items | -765 | -815 | -1,137 | -1,133 | -2,072 | -1,640 | Upgrade
|
| Asset Writedown | -60 | - | -154 | -21 | -547 | -10 | Upgrade
|
| Other Unusual Items | 2 | 2 | 5 | 38 | 49 | 90 | Upgrade
|
| Pretax Income | -823 | -813 | -1,286 | -1,116 | -2,570 | -1,560 | Upgrade
|
| Income Tax Expense | 2 | 2 | 2 | 2 | 1 | 1 | Upgrade
|
| Earnings From Continuing Operations | -825 | -815 | -1,288 | -1,118 | -2,571 | -1,561 | Upgrade
|
| Net Income | -825 | -815 | -1,288 | -1,118 | -2,571 | -1,561 | Upgrade
|
| Net Income to Common | -825 | -815 | -1,288 | -1,118 | -2,571 | -1,561 | Upgrade
|
| Shares Outstanding (Basic) | 283 | 261 | 213 | 193 | 187 | 176 | Upgrade
|
| Shares Outstanding (Diluted) | 283 | 261 | 213 | 193 | 187 | 176 | Upgrade
|
| Shares Change (YoY) | 20.81% | 22.73% | 10.45% | 2.76% | 6.31% | 8.14% | Upgrade
|
| EPS (Basic) | -2.92 | -3.12 | -6.05 | -5.80 | -13.71 | -8.85 | Upgrade
|
| EPS (Diluted) | -2.92 | -3.12 | -6.05 | -5.80 | -13.71 | -8.85 | Upgrade
|
| Free Cash Flow | -822 | -815 | -1,229 | -798 | -2,529 | -1,805 | Upgrade
|
| Free Cash Flow Per Share | -2.90 | -3.12 | -5.78 | -4.14 | -13.49 | -10.24 | Upgrade
|
| Gross Margin | -45.40% | -67.07% | -140.16% | -59.61% | -140.24% | - | Upgrade
|
| Operating Margin | -77.61% | -106.27% | -183.61% | -97.62% | -178.06% | -493.37% | Upgrade
|
| Profit Margin | -86.30% | -108.67% | -211.15% | -98.59% | -222.98% | -470.18% | Upgrade
|
| Free Cash Flow Margin | -85.98% | -108.67% | -201.47% | -70.37% | -219.34% | -543.67% | Upgrade
|
| EBITDA | - | - | - | -1,091 | -2,037 | -1,589 | Upgrade
|
| EBITDA Margin | - | - | - | -96.21% | -176.67% | - | Upgrade
|
| D&A For EBITDA | - | - | - | 16 | 16 | 49 | Upgrade
|
| EBIT | -742 | -797 | -1,120 | -1,107 | -2,053 | -1,638 | Upgrade
|
| EBIT Margin | -77.61% | -106.27% | -183.61% | -97.62% | -178.06% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.